



PATENT
ATTORNEY DOCKET NO. 50125/019001

Certificate of Mailing: Date of Deposit: 9/27/06

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Lombard
Printed name of person mailing correspondence

Colleen Lombard
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Michael Hallek et al.	Confirmation No.:	8894
Serial No.:	09/720,066	Art Unit:	1633
Filed:	October 19, 2001	Examiner:	M. Marvich
Customer No.:	21559		
Title:	AAV SCLEROPROTEIN, PRODUCTION AND USE THEREOF		

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Pursuant to 37 C.F.R. § 1.97(b)(4), this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 27 September 2006



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/019001
	Serial No.	09/720,066
	Applicant	Hallek et al.
	Filing Date	October 19, 2001
	Group	1633
	IDS Filed	September 27, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	"Designer" Gene Therapy May Target Specific Body Area," <i>Gene Therapy, Business News</i> , January 20, 2003. Vol. 2, pg. 1-8.
	Marshall, "Second Child In French Trial is Found to Have Leukemia," <i>Science</i> 299:320 (2003).
	Shi et al., "RGD Inclusion in VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism," <i>Molecular Therapy</i> 7:515-525 (2003).
	Steinbach et al., "Assembly of Adeno-Associated Virus Type 2 Capsids <i>in vitro</i> ," <i>Journal of General Virology</i> 78:1453-1462 (1997).
	White et al., "Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors," <i>Circulation</i> 109:513-519 (2004).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	